ProCE Banner Activity

ReFocus Phase I/II Trial of RLY-4008 in Patients With FGFR Inhibitor–Naive Cholangiocarcinoma With FGFR2 Alteration

Slideset Download
Conference Coverage
RLY-4008, a selective FGFR2 inhibitor, showed promising efficacy and safety in patients with FGFR inhibitor–naive cholangiocarcinoma with FGFR2 fusion or rearrangement in the phase I/II ReFocus trial.

Released: September 22, 2022

Expiration: September 21, 2023

No longer available for credit.
Begin Activity


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from


Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.